Dr. Jiafu Ji, Dr. Ziyu Li, and Dr.  Lin Shen from Peking Cancer Hospital have co-authored a research paper titled “Cadonilimab with chemotherapy in HER2-negative gastric or gastroesophageal junction adenocarcinoma: the phase 1b/2 COMPASSION-04 trial”, published online in Nature Medicine. The study addresses several critical clinical issues, such as the limited benefit of PD-1 monoclonal antibody treatment, the high incidence of adverse effects with PD-1 and CTLA-4 combination therapy, and the ineffectiveness of PD-1 combined with chemotherapy in patients with low or negative CPS scores. To tackle these challenges, the researchers innovatively employed a domestically developed PD-1/CTLA-4 dual-target antibody in the COMPASSION-04 study, marking the first clinical trial globally to evaluate this combination as a first-line treatment for advanced gastric cancer.

The release of studies like HIMALAYA has marked the beginning of the dual immunotherapy era in advanced liver cancer treatment. As the majority of Chinese liver cancer patients are diagnosed at an advanced stage, finding the optimal systemic therapy, including durvalumab, in combination with local therapies to further improve patient outcomes has become a research focus. At the 2024 European Society for Medical Oncology (ESMO) Annual Meeting, held from September 13 to 17 in Barcelona, Spain, Dr. Rongping Guo's team from Sun Yat-sen University Cancer Center presented the results of their HILL study (982P) in a poster session. The study demonstrated that the combination of durvalumab, lenvatinib, and hepatic arterial infusion chemotherapy (HAIC) achieved a 2-year overall survival (OS) rate of 94%, with manageable side effects, contributing valuable insights from China for the treatment of advanced liver cancer. Oncology Frontier invited Dr. Rongping Guo for an in-depth interview to discuss the study.

The 2024 European Society for Medical Oncology (ESMO) Annual Meeting was held from September 13-17 in Barcelona, Spain. As one of the largest and most prestigious global clinical oncology conferences, it showcased groundbreaking research from experts around the world, advancing the field of oncology. In the hematologic malignancy space, this year's ESMO also featured many key advancements, including research from China. One such study, led by Dr. Hongyan Tong from The First Affiliated Hospital of Zhejiang University Medical College, was selected for an oral presentation. The study explored the efficacy of Timdarpacept (IMM01) combined with azacitidine (AZA) as a first-line treatment for chronic myelomonocytic leukemia (CMML) (801 MO). Hematology Frontier had the opportunity to interview Dr. Maria Ma, one of the team members, who provided an in-depth explanation of the study.

The 2024 European Society for Medical Oncology (ESMO 2024) Annual Meeting will be held from September 13-17 in Barcelona, Spain. At this upcoming ESMO 2024 conference, Dr. Fei Ma from the Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College will present two Mini Oral reports (344MO, 349MO) on the novel Trop-2 antibody-drug conjugate (ADC) ESG401. These two studies not only highlight the significant efficacy of ESG401 in HER2-negative breast cancer with brain metastases but also reveal its broad potential application across different subtypes of metastatic breast cancer. This provides new treatment options for breast cancer patients and opens new directions for the research and development of Trop-2 ADC drugs. Oncology Frontier invited Dr. Fei Ma to introduce the key aspects of these two studies, and we look forward to his exciting presentation at ESMO 2024, contributing Chinese insights and expertise to global breast cancer treatment.

From September 13 to 17, 2024, the highly anticipated European Society for Medical Oncology (ESMO) Annual Meeting took place in Barcelona, Spain. At this prestigious event, three cutting-edge research projects led by Dr. Lin Shen from Peking Cancer Hospital were successfully selected for poster presentations, showcasing the remarkable contributions of Chinese scholars in the field of oncology. Dr. Lin Shen has always emphasized the importance of designing clinical research to solve practical clinical problems, and these three studies exemplify that scientific spirit in action. Oncology Frontier has meticulously compiled the core content of these posters to present readers with an academic feast and to share the latest advancements in oncology.

From August 2 to 4, 2024, the 7th Oncology Precision Diagnosis and Treatment and the 10th Breast Cancer Individualized Treatment Conference (COMB), hosted by the China Cancer Foundation and the Beijing Breast Disease Prevention and Treatment Society, took place in Beijing. This conference focused on the development of individualized precision treatment in the field of breast cancer in China. Dr. Jin Zhang from Tianjin Medical University Cancer Institute and Hospital chaired a session titled “New Concepts in Regional Management of Breast Cancer,” discussing the precise development of comprehensive regional treatment for breast cancer. At the conference, Oncology Frontier had the opportunity to interview Dr. Jin Zhang, who shared insights on the de-escalation in early breast cancer surgery and explored the current status of anti-HER2 therapy and its clinical practice in advanced breast cancer.

At the 2024 European Society for Medical Oncology (ESMO) Annual Congress, Dr. Hitomi Sakai from the Advanced Cancer Translational Research Institute in Japan reported on the significant efficacy of the OLZ-based triple therapy in preventing treatment-related nausea and vomiting (NV) in patients treated with T-DXd, providing an important reference for clinical practice. After the conference, Dr. Hitomi Sakai was interviewed by Oncology Frontier, where she introduced the research process and related results.

At the 2024 ESMO Congress, Dr. Peter Schmid from Barts Cancer Institute, Queen Mary University of London shared the overall survival data from the KEYNOTE-522 study with a follow-up of 75.1 months. The long-term follow-up results of the study showed that the combination of immunotherapy and chemotherapy significantly extended the event-free survival and overall survival of patients with triple-negative breast cancer, reducing the risk of recurrence and death. This breakthrough not only reaffirms the therapeutic position of immunotherapy in early triple-negative breast cancer but also points the way for further optimizing treatment plans in the future, bringing longer survival hopes for patients. Oncology Frontier specially invited Dr. Peter Schmid to share the relevant data.